PETX - Aratana Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.19
+0.13 (+2.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.06
Open5.13
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.08 - 5.24
52 Week Range3.67 - 7.67
Volume472,499
Avg. Volume440,801
Market Cap237.984M
Beta2.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 5 Drug Stocks Poised to Surpass on Earnings This Quarter
    InvestorPlace8 days ago

    5 Drug Stocks Poised to Surpass on Earnings This Quarter

    This prospective upside marks the maximum quarterly earnings growth pace in seven years. The report further predicts that 11 of the 16 Zacks sectors are projected to exhibit double-digit earnings growth in the to-be-reported quarter.

  • Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
    Zacks28 days ago

    Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session

    Aratana Therapeutics (PETX) was a big mover last session, as the company saw its shares rise more than 12% on the day amid huge volumes.

  • Benzinga29 days ago

    Pet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In Upgrade

    Aratana Therapeutics Inc (NASDAQ: PETX ), which has a portfolio treatments for pet diseases and disorders, is likely to ride high on product momentum, according to Stifel.  The Analyst Analyst Jonathan ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMT

    Q4 2017 Aratana Therapeutics Inc Earnings Call

  • American City Business Journalslast month

    Aratana raises $11.7M despite aborted stock offering

    The funds were raised through the sale of 2.39 million shares via an at-the-market sales agreement with Cowen and Co. LLC. The agreement, which Aratana (PETX) entered in December, would allow the company incrementally to sell up to $50 million worth of shares. Considering the most recent sales, Aratana may sell the remaining $38 million in stock.

  • Aratana raises $11.7M despite aborted stock offering
    American City Business Journalslast month

    Aratana raises $11.7M despite aborted stock offering

    Aratana Therapeutics Inc., a Leawood-based animal health company (Nasdaq: PETX), raised $11.7 million through a stock sales agreement.

  • Associated Presslast month

    Aratana reports 4Q loss

    On a per-share basis, the Leawood, Kansas-based company said it had a loss of 37 cents. Losses, adjusted for asset impairment costs, came to 19 cents per share. The results surpassed Wall Street expectations. ...

  • When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?
    Simply Wall St.last month

    When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?

    Aratana Therapeutics Inc’s (NASDAQ:PETX): Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium.Read More...

  • Benzingalast month

    Aratana Therapeutics Q4 Earnings Preview

    Aratana Therapeutics (NASDAQ: PETX ) announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Analysts covering ...

  • American City Business Journals2 months ago

    Aratana builds pet drug pipeline by buying rights from Japanese company

    Aratana Therapeutics Inc. bought exclusive rights to develop a pain and inflammation treatment from Japanese drug developer AskAt Inc. The deal is part of a broader research-and-development agreement Aratana launched with AskAt. The partnership will stock Aratana's pipeline with human health compounds developed by AskAt that have the potential to treat pain, allergies and cancer in animals.

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool3 months ago

    3 Top Healthcare Stocks to Buy Right Now

    The S&P 500's top-performing stock last year and two under-the-radar small caps could be worth a closer look.

  • Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
    Zacks3 months ago

    Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod

    Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT

    Q3 2017 Aratana Therapeutics Inc Earnings Call

  • 3 Stocks That Feel Like Microsoft in 1986
    Motley Fool4 months ago

    3 Stocks That Feel Like Microsoft in 1986

    Two specialized small-cap drug developers, and a financial holding company share similar traits to software giant Microsoft from three decades ago.

  • American City Business Journals4 months ago

    When will Kansas, Missouri exhaust funding for children's health insurance?

    Kansas and Missouri have just a few months until funding for children's health insurance runs dry. Congress has not yet renewed funding for the Children's Health Insurance Program (CHIP), which provides coverage to about 79,000 kids in Kansas and 88,000 in Missouri. The program provides more matching federal money to states than Medicaid, and it covers health insurance for children whose families make too much to qualify for Medicaid but still don’t have access to private insurance.

  • American City Business Journals4 months ago

    Aratana's stock falls after newest pet drug treatment fails study

    Aratana Therapeutics Inc.'s newest treatment for dogs failed an effectiveness study, the Leawood animal health company announced Friday. Its latest drug candidate, a fat-derived stem cell treatment, was intended to treat dogs with advanced osteoarthritis. The treatment, dubbed AT-016, had entered pivotal trials, meaning the data would be used as evidence for approval by the Food and Drug Administration.

  • Why Momo, Aratana Therapeutics, and Sea Limited Slumped Today
    Motley Fool5 months ago

    Why Momo, Aratana Therapeutics, and Sea Limited Slumped Today

    What sent these stocks lower on a strong market day?

  • Why Aratana Therapeutics Inc. Is Tanking Today
    Motley Fool5 months ago

    Why Aratana Therapeutics Inc. Is Tanking Today

    Shares tumble after the company announces that it is tapping shareholders for cash.

  • Capital Cube5 months ago

    ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Aratana Therapeutics, Inc. Here are 5 ETFs with the largest exposure to PETX-US. Comparing the performance and risk of Aratana Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • American City Business Journals6 months ago

    With three products out, Aratana chases its fourth: a canine cancer drug

    With its third FDA-approved drug on the market, Aratana Therapeutics is hunting its next product, a canine cancer immunotherapy treatment. The treatment, called AT-014, would be used to treat bone cancer, or osteosarcoma, in dogs. Aratana (PETX) expects to obtain conditional licensure for the treatment from the U.S. Department of Agriculture before the end of 2017, which would allow the company to launch a safety study within a group of veterinary oncologists.

  • Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
    Capital Cube6 months ago

    Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017

    Categories: Yahoo FinanceGet free summary analysis Aratana Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aratana Therapeutics, Inc. – Zoetis, Inc. Class A, Eli Lilly and Company, Heska Corporation and Merck & Co., Inc. (ZTS-US, LLY-US, HSKA-US and MRK-US) that have also reported ... Read more (Read more...)

  • Associated Press6 months ago

    Aratana reports 3Q loss

    On a per-share basis, the Leawood, Kansas-based company said it had a loss of 21 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...